Format

Send to:

Choose Destination
See comment in PubMed Commons below
PLoS One. 2014 Jan 27;9(1):e87334. doi: 10.1371/journal.pone.0087334. eCollection 2014.

Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.

Author information

  • 1Irsicaixa AIDS Research Institute - HIVACAT, Autonomous University of Barcelona, Badalona, Spain ; Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • 2Lluita contra la SIDA Foundation, HIV Unit, University Hospital Germans Trias i Pujol, Badalona, UAB, Badalona, Spain.
  • 3Irsicaixa AIDS Research Institute - HIVACAT, Autonomous University of Barcelona, Badalona, Spain ; Lluita contra la SIDA Foundation, HIV Unit, University Hospital Germans Trias i Pujol, Badalona, UAB, Badalona, Spain ; University of Vic, Vic, Spain.
  • 4Irsicaixa AIDS Research Institute - HIVACAT, Autonomous University of Barcelona, Badalona, Spain.
  • 5Irsicaixa AIDS Research Institute - HIVACAT, Autonomous University of Barcelona, Badalona, Spain ; University of Vic, Vic, Spain ; Institució Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain.
  • 6Irsicaixa AIDS Research Institute - HIVACAT, Autonomous University of Barcelona, Badalona, Spain ; University of Vic, Vic, Spain.
  • 7Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.
  • 8Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • 9HIV/GUM Department, Chelsea and Westminster Hospital, London, United Kingdom.

Abstract

BACKGROUND:

The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown.

METHODS:

Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation).

RESULTS:

Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8⁺ T cells were indistinguishable between the two arms and did not change over time between the groups.

CONCLUSIONS:

Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies.

PMID:
24475275
[PubMed - indexed for MEDLINE]
PMCID:
PMC3903883
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk